2C-T-7
2,5-dimethoxy-4-propylthiophenethylamine
Viewing r1 — Apr 26, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
2C-T-7 (2,5-dimethoxy-4-(n)-propylthiophenethylamine) — Beautiful, Blue Mystic, T7 — is a synthetic psychedelic of the phenethylamine class. It is a thioalkyl-substituted relative of mescaline, distinguished by its prolonged duration and empathogenic character. 2C-T-7 is a partial agonist at serotonin 5-HT₂A receptors,[1][2][3] producing its effects by disrupting default sensory filtering and amplifying perceptual processing.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
DOI, 2C-B, mescaline +2 moreDOI, 2C-B, mescaline, LSD, psilocybin show less
Alexander Shulgin synthesized and self-tested the compound in 1986, later designating it one of his "magical half-dozen" most important phenethylamines.[4] Three fatalities in the United States between 2000 and 2001 — all involving insufflation and/or co-intoxicants — triggered emergency scheduling.[5][6] It is now Schedule I in the United States and controlled internationally under the UN Convention on Psychotropic Substances.[7]
Subjective effects include geometric visual patterns, color enhancement, empathogenic warmth, and introspective thought. The experience unfolds as a slow-building, crystalline clarity with prosocial openness that Shulgin considered qualitatively distinct from both Mescaline and LSD.[8] Nausea during onset and anxiety at higher doses are the most consistently reported unsought effects.
2C-T-7 produces no physical dependence, and rapid tolerance makes compulsive use self-limiting[9] — no lethal dose has been established, though three deaths occurred under high-risk conditions.[5] Its dual action as a serotonin receptor agonist and monoamine oxidase inhibitor[10][11] creates a pronounced serotonin syndrome risk when combined with other serotonergic substances, a hazard not shared by most psychedelic phenethylamines. No clinical studies have been conducted; the entire evidence base rests on animal pharmacology, Shulgin's self-reports, and informal community surveys.
History[edit]
Discovery
Alexander Shulgin first synthesized 2C-T-7 and conducted initial human trials in early 1986, beginning with inactive doses of 2–4 mg before reaching full psychedelic effects at 20–25 mg.[4] He documented the compound in PiHKAL as one of his "magical half-dozen" — the six phenethylamines he considered most important, alongside mescaline, 2C-B, and 2C-T-2.[4] No academic pharmacological investigation followed; the compound remained a research curiosity for approximately a decade.
Recreational Circulation and Fatalities
2C-T-7 entered recreational use in the late 1990s through Dutch smart shops before spreading to the United States.[5] Casey Hardison conducted an informal survey of 48 bioassays at an entheogen gathering in 2000, documenting doses of 25–45 mg with onset at 1–2 hours and duration of 8–12 hours.[8] Between late 2000 and April 2001, three deaths in the United States were associated with the compound — all involving insufflated doses of ≥30 mg and/or co-ingestion of MDMA or sympathomimetic stimulants.[12][5][6]
Scheduling
The DEA placed 2C-T-7 into temporary Schedule I on September 20, 2002,[13] followed by permanent placement on March 18, 2004.[7] The EMCDDA conducted a formal risk assessment in 2003,[14] leading to EU-wide control measures through Council Decision 2003/847/JHA.[15]
The "2C" prefix, coined by Shulgin, denotes the two-carbon chain between the phenyl ring and amino group shared by all members of the series.[4] The "T-7" designates the seventh thio-substituted compound in his systematic exploration of the 4-position. Street names that circulated during its brief market appearance included "Beautiful," "Blue Mystic," "Tripstay," and "Tweety-Bird Mescaline".[5]
Chemistry[edit]
Structural Class
2C-T-7 belongs to the 2C family of 2,5-dimethoxy-substituted phenethylamines — a series sharing the dimethoxyphenethylamine scaffold that also underlies mescaline. The 2C-T subclass is defined by a sulfur atom at the 4-position of the phenyl ring; 2C-T-7 carries a propylthio (–SCH₂CH₂CH₃) group there, distinguishing it from 2C-T-2 (ethylthio) and 2C-T-4 (isopropylthio).
The sulfur atom contributes substantial lipophilicity compared to oxygen- or halogen-substituted analogs like 2C-B, influencing both receptor binding characteristics and metabolic fate.[16]
Molecular Properties
| Molecular formula | C₁₃H₂₁NO₂S |
| Molecular weight | 255.38 g/mol |
The molecule consists of a phenyl ring bearing methoxy groups at the 2- and 5-positions, a propylthioether at the 4-position, and a two-carbon ethylamine side chain. The compound is achiral — it has no stereocenters, so no distinction between active and inactive mirror-image forms applies.
Structure–Activity Relationships
Shulgin's systematic exploration of the 4-position found the propyl chain length optimal for psychoactive potency within the 2C-T series.[4] Later receptor binding studies confirmed that propyl analogs achieve the highest 5-HT₂A activation potencies within the 4-alkyl-2,5-dimethoxy series.[17]
No peer-reviewed data on melting point, aqueous solubility, or long-term stability have been published for either the free base or hydrochloride salt.citation needed
Pharmacology[edit]
Mechanism of Action
2C-T-7 activates serotonin 5-HT₂A receptors as a partial agonist — the same primary target responsible for the psychedelic effects of LSD, mescaline, and 2C-B. In drug discrimination studies, rhesus monkeys treated with 2C-T-7 responded identically to animals given the reference 5-HT₂A agonist DOM, and a selective 5-HT₂A blocker fully reversed these effects.[1][2][3]
The compound also triggers the head-twitch response in rodents — a standard behavioral marker of 5-HT₂A activation.[18][19] At the cellular level, it engages phospholipase C and phospholipase A₂ signaling, though with lower efficacy than its amphetamine-class counterparts.[20]
MAO Inhibition
Unlike most psychedelic phenethylamines, 2C-T-7 inhibits both MAO-A and MAO-B — the enzymes responsible for breaking down serotonin, dopamine, and norepinephrine.[10] This dual action — directly activating serotonin receptors while simultaneously slowing serotonin breakdown — creates a compounding serotonergic load not present with compounds like 2C-B or Mescaline.
Pharmacokinetics
No human pharmacokinetic studies have been published. Onset time, bioavailability, plasma half-life, and elimination rate have not been measured in controlled settings.
MAO-A and MAO-B are the principal enzymes responsible for 2C-T-7's breakdown, with CYP2D6 contributing a minor role.[11] In rat studies, the major metabolic pathways involve hydroxylation of the propyl side chain, oxidative deamination, and S-dealkylation.[21] The principal urinary metabolite in rats is a β-hydroxylated-N-acetylated-sulfoxide[22] — a profile distinct from closely related 2C-T-2 and 2C-T-4, demonstrating metabolite specificity within the 2C-T series despite shared structural features.
Neuroscience[edit]
Where It Acts
No neuroimaging studies of 2C-T-7 have been conducted. Based on its confirmed 5-HT₂A agonism,[1][2][3] the compound is expected to act primarily on layer V pyramidal neurons in the prefrontal cortex — disrupting the default mode network, reducing the thalamus's filtering of sensory information, and increasing the overall diversity of cortical signaling.citation needed
Its monoamine oxidase inhibitory properties[10] may elevate serotonin, dopamine, and norepinephrine simultaneously, potentially contributing to the stimulant-like energy and empathogenic warmth reported by users.[8]
Why It Matters
The REBUS (Relaxed Beliefs Under Psychedelics) model proposes that serotonergic psychedelics loosen the brain's top-down expectations, allowing raw sensory input to shape experience more freely.citation needed 2C-T-7's partial 5-HT₂A agonism would produce this effect, consistent with reported heightening of sensory perception and dissolution of rigid thought patterns.
Serotonergic psychedelics also promote structural changes in neurons — increased branching and new synaptic connections — via 5-HT₂A-dependent signaling.citation needed Whether 2C-T-7 specifically drives this neuroplasticity has not been tested, but the effect is demonstrated for closely related phenethylamines.
- Does 2C-T-7 promote structural neuroplasticity, and at what doses?
- How does its combined 5-HT₂A agonist / MAO inhibitor profile affect brain dynamics compared to pure 5-HT₂A agonists like LSD?
- Does the 8–15 hour duration reflect slow receptor unbinding, sustained blood levels, or both?
- What accounts for the empathogenic warmth not prominent in structurally similar 2C-B?
Subjective Effects[edit]
2C-T-7 produces a psychedelic state defined by empathogenic warmth and introspective depth. At lower oral doses, the experience favors gentle sensory enhancement and prosocial openness; at higher doses, intense geometric visuals and deep introspection predominate, with the balance between warmth and anxiety strongly modulated by set and setting.[8][23]
Among the 2C phenethylamines, 2C-T-7 sits closer to mescaline in introspective character than to the shorter, more visually focused 2C-B. Shulgin considered its "crystalline" thought quality and prosocial feeling qualitatively distinct from most members of its class[4] — though these characterizations rest entirely on self-report data rather than controlled comparison.
Effect Grid
At common oral doses (15–25 mg), the full psychedelic experience manifests: pronounced colour enhancement and saturation, geometric visual patterning overlaying surfaces, drifting and morphing of objects, and closed-eye visuals with intricate detail. Empathogenic and prosocial effects become prominent — a quality Shulgin specifically noted as distinguishing 2C-T-7 from other phenethylamines. Thought connectivity and introspection deepen, with a reported "crystalline" clarity.
Nausea is one of the most common adverse effects at this range, typically peaking during the come-up (1–2 hours post-ingestion). Muscle tension, jaw clenching, and stimulatory cardiovascular effects (increased heart rate, mild blood pressure elevation) are frequently reported. Duration is 8–12 hours; sleep is unlikely for the first 10–12 hours.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Holotropic state · Tracers · Environmental patterning · Music enhancement · Visual breathing · Touch enhancement · After-images · Symmetrical texture repetition · Auditory enhancement · Brightness alteration · Depth perception distortion · Light sensitivity · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Sound sensitivity · Visual melting · Visual morphing · Auditory distortion · Auditory misinterpretation · Peripheral misidentification · Spatial disorientation · Vestibular distortion · Visual diffraction · Visual haze / noise · Dreaming enhancement · Synesthesia · Visual acuity suppression · Visual magnification · Visual processing acceleration · Visual acuity enhancement · Flashbacks · Object transformations · Internal hallucinations · Environmental orbism / cubism · External hallucinations · Object activation · Auditory hallucinations · Perspective hallucinations · Visual processing suppression · Visual recursion · Visual scenery slicing · Persisting hallucinations
Visual breathing · Touch enhancement · After-images · Symmetrical texture repetition · Auditory enhancement · Brightness alteration · Depth perception distortion · Light sensitivity · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Sound sensitivity · Visual melting · Visual morphing · Auditory distortion · Auditory misinterpretation · Peripheral misidentification · Spatial disorientation · Vestibular distortion · Visual diffraction · Visual haze / noise · Dreaming enhancement · Synesthesia · Visual acuity suppression · Visual magnification · Visual processing acceleration · Visual acuity enhancement · Flashbacks · Object transformations · Internal hallucinations · Environmental orbism / cubism · External hallucinations · Object activation · Auditory hallucinations · Perspective hallucinations · Visual processing suppression · Visual recursion · Visual scenery slicing · Persisting hallucinations
Wakefulness · Body high · Spontaneous body sensations · Body schema distortion · Muscle tension · Appetite suppression · Dizziness · Excessive sweating · Bruxism · Bodily heaviness · Bodily pressures · Dry mouth · Heart rate perception changes · Insomnia · Laughter fits · Physical fatigue · Restlessness · Tactile euphoria · Tingling / electric sensations · Vibrations / buzzing · Headache · Involuntary body movements · Dehydration sensation · Breathing alteration · Sexual arousal enhancement · Trembling · Vasoconstriction · Vomiting · Diarrhea · Increased urination · Watery eyes · Bodily lightness · Salivation · Sedation · Yawning · Abnormal heartbeat · Bodily dissociation · Tactile hallucination
Body schema distortion · Muscle tension · Appetite suppression · Dizziness · Excessive sweating · Bruxism · Bodily heaviness · Bodily pressures · Dry mouth · Heart rate perception changes · Insomnia · Laughter fits · Physical fatigue · Restlessness · Tactile euphoria · Tingling / electric sensations · Vibrations / buzzing · Headache · Involuntary body movements · Dehydration sensation · Breathing alteration · Sexual arousal enhancement · Trembling · Vomiting · Diarrhea · Increased urination · Watery eyes · Bodily lightness · Salivation · Sedation · Yawning · Abnormal heartbeat · Bodily dissociation · Tactile hallucination
Conceptual thinking · Aesthetic enhancement · Thought acceleration · Cognitive euphoria · Cognitive flexibility · Introspection enhancement · Multiple thought streams · Openness enhancement · Thought connectivity · Memory suppression · Thought loops · Cognitive fatigue · Cognitive impairment · Confusion · Focus suppression · Increased nature relatedness · Information processing suppression · Memory fragmentation · Thought disorganization · Analysis enhancement · Creativity enhancement · Analysis suppression · Cognitive dysphoria · Humor enhancement · Motivation suppression · Synchronicity · Language suppression · Memory replays · Thought deceleration · Focus enhancement · Information processing enhancement · Delusions · Amnesia · Delirium
Cognitive euphoria · Cognitive flexibility · Introspection enhancement · Multiple thought streams · Openness enhancement · Thought connectivity · Memory suppression · Thought loops · Cognitive fatigue · Cognitive impairment · Confusion · Focus suppression · Increased nature relatedness · Information processing suppression · Memory fragmentation · Thought disorganization · Analysis enhancement · Creativity enhancement · Analysis suppression · Cognitive dysphoria · Humor enhancement · Motivation suppression · Synchronicity · Language suppression · Memory replays · Thought deceleration · Focus enhancement · Information processing enhancement · Amnesia · Delirium
Empathy enhancement · Simultaneous emotions · Catharsis · Dysphoria · Irritability
Irritability
Communication suppression · Social connection · Trust enhancement · Communication enhancement · Sociability enhancement · Sociability suppression · Social disconnection · Flow state · Boundary dissolution · Identity alteration · Cognitive disconnection · Ego dissolution
Sociability enhancement · Sociability suppression · Social disconnection · Flow state · Boundary dissolution · Identity alteration · Cognitive disconnection · Ego dissolution
Time cessation
Entity contact · Non-dual awareness · Cessation · Death-rebirth sequence · Voidness · Near-death experience
Voidness · Near-death experience
Recursive awareness
Timeline
First alerts appear 30–90 minutes after ingestion: mild mood shift, slight body awareness, faint colour brightening. Easily overlooked or attributed to anticipation.
Effects build steadily over 45–90 minutes. Nausea peaks during this phase and is among the most common complaints. Colour enhancement and geometric patterning begin to emerge.
Maximum intensity sustained for 2–4 hours. Visual patterning, colour saturation, empathogenic warmth, and introspective depth reach their apex. Thought connectivity and emotional intensity are highest.
Effects remain clearly present but gradually diminishing over 2–3 hours. Visual effects soften. Empathogenic and introspective qualities persist.
A gentle descent over 1. 5–3 hours. Perceptual effects fade to occasional traces.
Residual mood elevation, reflective thinking, and mild fatigue may persist for 4–12 hours after primary effects resolve. Sleep quality may be reduced.
⚠ Do not drive or operate heavy machinery for at least 24 hours after ingestion, as subtle cognitive impairment may persist beyond subjective awareness.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- DOI · 2C-B · mesc
Toxicity
Acute Toxicity
No LD₅₀ has been established for 2C-T-7 in any species, and no therapeutic index can be calculated. Three fatalities occurred in the United States between late 2000 and April 2001.[12][5][6] All involved insufflated doses of ≥30 mg and/or co-intoxication with MDMA or sympathomimetic stimulants. One confirmed single-substance death followed insufflation of an excessive dose.[5]
No deaths have been reported from oral use at conventional doses (10–30 mg) in the absence of co-intoxicants.
Cell-Based Toxicity
Laboratory testing in neuronal cell cultures found concentration-dependent cell death, energy depletion, disrupted calcium regulation, and signs of oxidative stress at high concentrations.[24] These concentrations greatly exceeded estimated brain levels at typical human doses; direct translation to real-world toxicity risk is not established.
Psychological Risks
Anxiety and panic attacks are documented at higher doses.[5][23] Paranoid thinking has been noted.[5] Overwhelming visual intensity at strong doses can precipitate acute psychological crisis.
No published data address psychosis risk, worsening of pre-existing psychiatric conditions, or lasting perceptual disturbances (HPPD) specifically for 2C-T-7. The 8–15 hour duration means individuals who experience distress face a prolonged period without pharmacological termination options beyond sedation with benzodiazepines.
Tolerance and Dependence
Tolerance develops rapidly through 5-HT₂A downregulation. In mice, daily administration produces tolerance to the head-twitch response, and cross-tolerance with other phenethylamine hallucinogens is bidirectional and insurmountable — increasing the dose cannot overcome it.[9] Phenethylamine hallucinogens develop tolerance more rapidly than tryptamines.[9]
Community estimates suggest a tolerance half-life of approximately 3 days and full reset at 7 days.citation needed These timelines lack experimental confirmation.
No studies have examined physical or psychological dependence. The compound shows no significant activity at dopamine, serotonin, or norepinephrine transporters,[25] suggesting negligible engagement of reward circuitry. The characterization as not habit-forming is inferred from the serotonergic psychedelic class.inferred
Drug Interactions
The combination of 5-HT₂A agonism and monoamine oxidase inhibition gives 2C-T-7 an elevated interaction risk compared to phenethylamine psychedelics without MAO activity.
MAO Inhibitors
2C-T-7 is primarily broken down by MAO-A and MAO-B.[11] Co-administration with pharmaceutical MAO inhibitors (phenelzine, tranylcypromine, selegiline, moclobemide) or natural MAO inhibitors (harmine, harmaline) would block its primary elimination pathway, causing unpredictable plasma level spikes. Combined with the compound's own MAO-inhibiting and serotonin-activating properties, this creates severe serotonin syndrome risk.[10][11]
MDMA
Two of three documented deaths involved MDMA co-ingestion.[6][26] The combination compounds serotonergic loading through MDMA's serotonin release and 2C-T-7's receptor activation and MAO inhibition. Cardiovascular stress is amplified.
Sympathomimetic Stimulants
One fatality involved co-ingestion of ephedrine/guaifenesin.[6] Amphetamines, cocaine, and other stimulants increase cardiovascular strain alongside 2C-T-7's psychedelic state.
Serotonergic Medications
SSRIs, SNRIs, lithium, tramadol, linezolid, and dextromethorphan all elevate serotonin syndrome risk when combined with 2C-T-7.[27] SSRIs may also blunt 2C-T-7's psychedelic effects through chronic 5-HT₂A downregulation.
CYP2D6 Interactions
CYP2D6 plays a minor role in 2C-T-7 metabolism.[11] Strong CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, quinidine) could slow clearance, but this is likely secondary to MAO-pathway interactions given MAO's dominant metabolic role.
Contraindications
Absolute contraindications: concurrent MAO inhibitor use,[11][10] concurrent MDMA use,[6] personal or family history of psychotic disorders,safety citation needed and concurrent lithium use.safety citation needed
Relative contraindications: concurrent SSRI or SNRI use,[27] cardiovascular disease, epilepsy or seizure disorders, liver impairment, pregnancy and breastfeeding (no safety data), and adolescence (no safety data; one fatality involved a 17-year-old[26]).
Harm Reduction[edit]
Forms & Identification
Most 2C-T-7 encountered historically appeared as a white to off-white powder (hydrochloride salt) or pressed tablets. The compound is visually indistinguishable from dozens of other white-powder phenethylamines, making reagent testing essential before use.
The difference between an active oral dose and the insufflated doses associated with fatalities is a matter of milligrams — precision weighing with a milligram-scale balance is non-negotiable for powder forms. Any material that cannot be weighed accurately should not be consumed.
Guidelines
- Test all material with reagent kits before use. A milligram-scale balance (±1 mg precision) is essential — never estimate powder doses by eye.
- Start with a low oral dose and wait at least 2.5 hours before considering any adjustment. Onset is slow and variable; premature redosing is a primary risk factor for overdose.
- Oral administration is strongly preferred. All three documented fatalities involved insufflation, which delivers a more rapid and intense — and less controllable — dose escalation.
- Eat lightly 2–3 hours beforehand to reduce nausea without dosing on a full stomach.
- Keep benzodiazepines accessible as a safety net for unmanageable anxiety (e.g. diazepam 5–10 mg oral).
- Have a clear plan for the full duration — 8–15 hours is a significant commitment that spans daylight and nighttime hours.
Set & Setting
The 8–15 hour duration demands realistic planning. Choose a safe, comfortable, familiar environment with no obligations for the full day and the following morning. A trusted, sober companion is strongly recommended, particularly at higher doses where anxiety and overwhelming visuals become more likely.
Nausea during onset is common — having water, ginger, and a quiet space to lie down reduces discomfort during the come-up.
Aftercare & integration. The extended duration can leave users physically and mentally exhausted. Prioritize sleep, hydration, and light nutrition in the 24 hours following the experience. Mild mood shifts — either elevated or subdued — are common for 1–2 days afterward.
For psychologically significant experiences, journaling within the first 48 hours helps capture insights before they fade. If the experience was distressing or brought up difficult material, talking with a trusted person or a psychedelic integration therapist can help process what emerged. Persistent anxiety, depersonalization, or visual disturbances lasting more than a week warrant professional consultation.
Recovery & Support
2C-T-7 is not considered physically addictive, and rapid tolerance makes compulsive daily use self-limiting. If use has become a pattern of avoidance or emotional regulation, peer support communities such as psychedelic integration circles or harm reduction organizations can help.
For broader substance use concerns, SAMHSA's National Helpline (1-800-662-4357) provides free, confidential referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Uncomfortable anxiety and nausea are common and usually pass. Seek immediate help if any of the following occur: seizures, loss of consciousness, rigid or jerking muscles, chest pain, severe confusion with inability to communicate, self-harm behavior, or body temperature that feels dangerously hot to touch.
Immediate steps:
- Call emergency services immediately if seizures, unconsciousness, or severe overheating occur.
- Place an unconscious but breathing person in the recovery position (on their side, airway clear).
- Do not restrain a conscious person unless they are in immediate danger of harming themselves.
- Keep the environment calm, quiet, and cool. Remove excess clothing if overheating.
- Do not induce vomiting.
What to tell the dispatcher: Name the substance (2C-T-7 — a psychedelic phenethylamine), approximate dose and time of ingestion, route of administration, any other substances taken, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
2C-T-7 is controlled internationally under the United Nations 1971 Convention on Psychotropic Substances (Schedule II, added October 2009) and is independently scheduled or covered by structural analog legislation in most major jurisdictions. Scheduling was driven primarily by the three US fatalities in 2000–2001 and the EMCDDA risk assessment of 2003.[14][12]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Temporary placement September 20, 2002;[13] permanent March 18, 2004.[7] No accepted medical use per DEA. |
| European Union | Controlled per Council Decision 2003/847/JHA | EU-wide control measures enacted November 27, 2003 following EMCDDA risk assessment.[15] |
| United Kingdom | Controlled under MDA 1971; Psychoactive Substances Act 2016 | Covered by generic phenethylamine definitions in the Misuse of Drugs Act 1971; additional blanket coverage under the Psychoactive Substances Act 2016.[12] |
| Germany | Anlage I BtMG (Schedule I equivalent) | Controlled since July 1, 2001.citation needed |
| Netherlands | Banned | Among the first jurisdictions to ban 2C-T-7 from smart shop sale, circa 2000–2001.citation needed |
| Canada | Schedule III (CDSA) | Controlled since October 12, 2016.citation needed |
| Australia | Analog drug laws | Not specifically named; controlled as a structural analog of scheduled phenethylamines.citation needed |
| United Nations | Schedule II (1971 Convention) | Added October 2009.citation needed |
2C-T-7 was among nine phenethylamines submitted for EMCDDA risk assessment, with all except MBDB recommended for EU-wide control.[12]
references
- [1] ^abcLi JX, Rice KC, France CP (2009) Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rhesus monkeys: antagonism and apparent pA2 analyses. — Journal of pharmacology and experimental therapeutics doi:10.1124/jpet.108.145458
- [2] ^abcLi JX, Rice KC, France CP (2008) Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rhesus monkeys — The Journal of Pharmacology and Experimental Therapeutics PMID:17993605
- [3] ^abcLi JX, Koek W, Rice KC, France CP (2010) Differential effects of serotonin 5-HT1A receptor agonists on the discriminative stimulus effects of the 5-HT2A receptor agonist 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rats and rhesus monkeys. — Journal of pharmacology and experimental therapeutics doi:10.1124/jpet.109.163451
- [4]
- [5]
- [6]